DEA Cannabis Rescheduling 2026: The Hearing Is Over — Here's What Comes Next

The DEA cannabis rescheduling 2026 process just cleared a major milestone. The formal administrative hearing on moving cannabis from Schedule I to Schedule III of the Controlled Substances Act wrapped on July 15, 2026, after 17 days of testimony in Arlington, Virginia. Now the process moves into its next critical phase: post-hearing briefs are due August 17, 2026, and after that, the country waits on an Administrative Law Judge recommendation that could reshape the federal legal landscape for cannabis.

If you're a cannabis consumer in DC, Maryland, or Virginia, this matters. Here's what happened, what comes next, and what a final Schedule III ruling would actually change for you.

---

What Happened at the DEA Hearing

The hearing ran from June 29 to July 15, 2026, presided over by Chief Administrative Law Judge (ALJ) Derek Julius. The DEA, which was the proponent of the rescheduling change, presented testimony from FDA scientists and medical experts arguing that cannabis meets the standard for "currently accepted medical use" — a key legal threshold required for Schedule III classification.

Seven "interested persons" were granted formal standing to participate in the hearing. All seven were opponents of rescheduling, including Smart Approaches to Marijuana (SAM) and the attorneys general of Nebraska, Idaho, Indiana, and Louisiana, according to reporting from Marijuana Moment (August 4, 2026). Pro-rescheduling organizations were largely denied formal participation by the ALJ.

That lopsided structure does not mean rescheduling is at risk. The DEA's own attorneys were making the affirmative case. But it does mean the formal hearing record leans heavily on opposition arguments, which the ALJ will weigh against the government's scientific and medical evidence.

The April 2026 Order: Medical Cannabis Is Already Schedule III

Before the hearing even began, a significant step was taken. On April 23, 2026, Acting Attorney General Todd Blanche signed an order formally moving FDA-approved cannabis products and state-licensed medical marijuana to Schedule III, according to the Federal Register Notice of Hearing published April 28, 2026.

That order is already in effect. If you hold a valid medical cannabis card in DC, Maryland, or Virginia, the product you're purchasing from a licensed dispensary is now federally classified as Schedule III, not Schedule I.

The July hearing focused specifically on adult-use and recreational cannabis, which was not covered by the April order. That piece is still working through the administrative process.

---

The August 17 Deadline: What Post-Hearing Briefs Are

On July 16, 2026, ALJ Derek Julius issued a post-hearing order setting August 17 as the deadline for post-hearing briefs, according to The Marijuana Herald. Here is what that means.

Designated parties — those granted formal standing in the hearing — may file written briefs of up to 50 pages. The briefs can include closing arguments and address issues raised during the 17 days of testimony. Filing is optional: a party that does not submit a brief will not be penalized, and silence simply signals no further submission was intended.

The deadline also covers proposed corrections to official hearing transcripts, limited strictly to transcription errors like misspelled words or incorrect speaker attribution. Substantive changes to testimony are not permitted.

Once the August 17 deadline passes, the record closes and the process moves to the ALJ's review phase.

---

What Comes Next: The Full Federal Cannabis Rescheduling Timeline

The DEA cannabis rescheduling timeline after August 17 moves through four stages.

Stage 1 — ALJ reviews the record. After the briefs are filed, Judge Julius reviews all testimony, evidence, and written arguments. There is no statutory deadline for this phase. Based on the complexity of the record and historical precedent for DEA rulemaking, the ALJ recommendation is projected for late 2026, though that timeline is not fixed.

Stage 2 — Objections period. Once the ALJ issues a recommended decision, parties have 20 days to file formal objections, called "exceptions," to the recommendation.

Stage 3 — Final determination by the DEA Administrator. DEA Administrator Terry Cole receives the complete record, including the ALJ recommendation and all objections, and makes the final agency decision on whether to publish a final rule for broader cannabis rescheduling.

Stage 4 — Legal challenges. Opponents have already filed petitions in the DC Circuit Court of Appeals challenging the April 2026 medical cannabis order. Those challenges could affect the timeline for any broader rescheduling rule taking effect, according to reporting from Legalink (July 30, 2026).

The short version: the hearing is over, but a final federal ruling on adult-use cannabis rescheduling is still months away, and possibly well into 2027.

---

What Cannabis Schedule III Rescheduling Would Actually Mean

This is where things get concrete. A full Schedule III reclassification would not make cannabis federally legal in the way many people imagine. Here is what it would and would not change.

What Changes Under Schedule III

IRS Section 280E relief. The most immediate financial impact of Schedule III reclassification is the elimination of the IRS Section 280E tax penalty for cannabis businesses. Under current law, Schedule I and II businesses cannot deduct ordinary business expenses. Medical cannabis operators already received this relief starting in 2026, according to IRS and Treasury guidance. A broader Schedule III ruling would extend that relief to adult-use operators as well.

For consumers, this matters because 280E has inflated retail prices across the industry. Businesses paying effective tax rates of 70 to 90 percent on revenue have had to pass some of that burden to customers. Lower tax burdens may eventually translate to more competitive pricing, though market timing will vary.

Banking access. Schedule III status reduces the "high-risk" profile that has historically made banks and payment processors reluctant to work with cannabis businesses. This is already improving for medical operators. A broader rescheduling would extend that shift to adult-use markets.

Federal acknowledgment of medical use. Rescheduling formally recognizes that cannabis has accepted medical utility under federal law. This reverses a Schedule I designation the government has maintained for decades.

What Does Not Change

Cannabis remains federally controlled. Schedule III is not federal legalization. Cannabis would still be regulated under the Controlled Substances Act.

Interstate commerce stays blocked. Even under Schedule III, cannabis cannot legally cross state lines. DC, Maryland, and Virginia dispensaries will continue to source from in-state supply chains for the foreseeable future.

State laws still govern your purchase. Whether you are buying from a licensed Maryland dispensary, a DC medical cannabis operator, or a Virginia medical shop, your rights and access are determined by state law, not federal scheduling status.

---

How Cannabis Rescheduling Affects DC, Maryland, and Virginia

Washington DC

The April 2026 order that moved medical cannabis to Schedule III has specific significance for DC. The "Harris Rider" — a provision in congressional spending bills that blocked DC from spending funds to regulate Schedule I cannabis — loses much of its legal basis when cannabis is no longer Schedule I. According to Marijuana Moment (August 4, 2026), this opens a potential path for DC to finally launch a taxed and regulated recreational retail market in late 2026 or 2027.

Bud Lords currently operates as a licensed internet retailer delivering to DC customers. Whatever the final federal ruling looks like, delivery of locally sourced, licensed cannabis products in DC continues under current DC law.

Maryland

Maryland launched adult-use cannabis sales in 2023. Licensed dispensaries in the state are now navigating the "dual-use" tax allocation question: medical sales qualify for 280E relief, while adult-use sales may not until a broader federal ruling is finalized. Maryland's Cannabis Administration has been working to provide guidance for operators during this transition.

The broader financial impact is significant. Maryland dispensaries operating with effective federal tax rates of 70 to 80 percent on revenue stand to see substantial profitability improvements as rescheduling extends to adult-use.

Virginia

Virginia's path to recreational retail is set: sales are scheduled to begin July 1, 2027, following a budget compromise signed in June 2026. Existing medical operators are expected to convert to hybrid medical-adult-use models by December 1, 2026, allowing them to prepare for the 2027 launch. Schedule III reclassification for medical cannabis means Virginia's current medical operators are already eligible for 280E relief as they prepare for that transition.

---

What This Means for You Right Now

The DEA hearing post-hearing briefs deadline of August 17, 2026 is the next firm milestone in a process that has been years in the making. Medical cannabis is already Schedule III. The hearing on adult-use rescheduling is complete. A final ALJ recommendation and DEA Administrator decision are expected in the months ahead.

For DC, Maryland, and Virginia cannabis consumers, the day-to-day experience of buying cannabis has not fundamentally changed because of these federal developments. You still buy from licensed dispensaries or licensed delivery services under state law. What is changing is the economic and regulatory foundation underneath those businesses, which will shape what is available, how it is priced, and how the market develops over the next two to three years.

This content is for general informational purposes only and does not constitute legal advice. Cannabis laws vary by jurisdiction and change frequently. Consult a licensed attorney for guidance on your specific situation.

---

Shop Bud Lords — DC, Maryland, and Virginia Delivery

Bud Lords delivers licensed cannabis products across the DMV region. Whether you're looking for flower, pre-rolls, edibles, or concentrates, same-day delivery is available in DC, Maryland, and Virginia.

Stay current on cannabis law and policy in the DMV at the Bud Lords Cannabis Newsroom. And visit budlords.com to browse the full menu and place your order.

This article was researched and written with AI assistance by the Bud Lords AI Newsroom.

---

Sources:

• Marijuana Moment, "What's Next for Marijuana Rescheduling," August 4, 2026. https://marijuanamoment.net

• The Marijuana Herald, "DEA Judge Sets August 17 Deadline for Post-Hearing Briefs," July 16, 2026. https://themarijuanaherald.com

• Federal Register, "Notice of Hearing: Rescheduling of Marijuana," April 28, 2026. https://www.federalregister.gov

• Harris Sliwoski LLP, "DEA's Marathon Hearing on Moving Marijuana to Schedule III Wraps July 15," July 14, 2026. https://harris-sliwoski.com

• Legalink, "DC Circuit Challenge and DEA Hearing Put Federal Cannabis Rescheduling to the Test," July 30, 2026. https://legalink.net

• Business of Cannabis, "DEA Rescheduling Hearing Closes as States' Own Witness Concedes Regulation Reduces Crime," July 15, 2026. https://businessofcannabis.com/dea-rescheduling-hearing-closes-as-states-own-witness-concedes-regulation-reduces-crime/